Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Carcinoma, Transitional Cell 9Carcinoma, Renal Cell 8Colorectal Neoplasms 7Urinary Bladder Neoplasms 6Ovarian Neoplasms 6Neoplasm Metastasis 6Squamous Cell Carcinoma of Head and Neck 4Recurrence 3Glioblastoma 3Carcinoma, Neuroendocrine 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Sarcoma 2Neuroendocrine Tumors 2Kidney Neoplasms 2Kidney Diseases 2Head and Neck Neoplasms 2Glioma 2Fallopian Tube Neoplasms 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Testicular Neoplasms 1Testicular Diseases 1

Interventions

Cisplatin 30Pemetrexed 21Gemcitabine 11Radiotherapy 6Nivolumab 6Drug Therapy 6Cyclophosphamide 6Carboplatin 6durvalumab 4Vinorelbine 4Chemotherapy, Adjuvant 4tumor necrosis factor-alpha, CNGRC fusion protein, human 3sodium thiosulfate 3sargramostim 3Ipilimumab 3Doxorubicin 3raltitrexed 2pembrolizumab 2cediranib 2SS1(dsFv)PE38 2Radiotherapy, Intensity-Modulated 2Psychiatric Rehabilitation 2Photochemotherapy 2Neoadjuvant Therapy 2Methotrexate 2Interferon-alpha 2Imatinib Mesylate 2Granulocyte-Macrophage Colony-Stimulating Factor 2Gefitinib 2Everolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Mesothelioma, Malignant × avelumab × Clear all
NCT03399552 2023-10-23

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
15 enrolled 8 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡